Prostate cancer remains one of the most commonly diagnosed cancers among men and continues to be an important area of oncology research.

Researchers investigate the molecular mechanisms, biomarkers, disease progression, treatment response, and resistance associated with prostate cancer to improve diagnosis and develop more effective therapies.

At Bay Biosciences, we provide high-quality, clinical-grade prostate cancer serum samples, prostate cancer plasma samples, peripheral blood mononuclear cells (PBMCs), tumor tissue, and other human biospecimens to support a wide range of research applications.

Understanding Prostate Cancer

Prostate cancer develops in the prostate gland, a small gland located below the bladder and in front of the rectum. The prostate surrounds part of the urethra and produces fluid that forms part of semen.

Most prostate cancers are adenocarcinomas, which develop from glandular cells within the prostate.

Some prostate cancers grow slowly and may remain confined to the prostate for many years.

However, other tumors can grow more rapidly and spread to nearby tissues or distant organs.

Prostate cancer cells may spread through the lymphatic system or bloodstream. When the disease metastasizes, it commonly affects the bones and may also involve other organs.

Prostate cancer samples

Prostate-Specific Antigen (PSA)

Prostate-specific antigen (PSA) is a protein produced by cells of the prostate gland.

Healthcare providers can measure PSA levels through a blood test. PSA testing is commonly used as part of prostate cancer screening and disease monitoring.

An elevated PSA level may occur in men with prostate cancer. However, prostate cancer is not the only condition that can increase PSA. Benign prostatic hyperplasia (BPH) and prostatitis can also result in elevated PSA levels.

Signs and Symptoms of Prostate Cancer

Early prostate cancer may not cause noticeable symptoms. As the disease progresses, some patients may develop urinary or other symptoms.

Common symptoms may include:

These symptoms can also occur with noncancerous prostate conditions. Therefore, clinical evaluation and appropriate diagnostic testing are required to determine the underlying cause.

Causes of Prostate Cancer

The exact cause of prostate cancer is not fully understood. However, the disease develops when genetic changes disrupt the normal regulation of prostate cell growth and division.

Firstly, mutations may affect genes that control cell growth, DNA repair, and cell survival. These changes can allow abnormal prostate cells to multiply uncontrollably.

Secondly, inherited genetic alterations can increase susceptibility to prostate cancer in some individuals. For example, alterations involving genes associated with DNA repair may contribute to an increased risk.

Thirdly, prostate cancer development is influenced by age and hormonal factors. Androgens, including testosterone, play an important role in prostate cell growth and continue to be investigated in prostate cancer research.

Finally, researchers continue to investigate interactions between genetic, environmental, lifestyle, and biological factors that may influence prostate cancer development and progression.

Risk Factors for Prostate Cancer

Several factors can increase an individual’s likelihood of developing prostate cancer.

Firstly, age is one of the strongest risk factors. The likelihood of prostate cancer increases as men get older.

Secondly, family history can influence risk. Men with a father, brother, or son diagnosed with prostate cancer may have a higher risk of developing the disease.

Thirdly, genetic factors can contribute to susceptibility. Certain inherited genetic changes are associated with increased prostate cancer risk.

Finally, race and ethnicity can influence prostate cancer risk and disease outcomes.

Research has shown differences in incidence and mortality among racial and ethnic groups.

Diagnosis of Prostate Cancer

The diagnosis of prostate cancer begins with a review of the patient’s medical history, symptoms, and risk factors.

Healthcare providers may then use several diagnostic approaches.

Firstly, a PSA blood test measures the concentration of prostate-specific antigen in the blood. Physicians may evaluate PSA levels alongside other clinical findings.

Secondly, a digital rectal examination (DRE) may be performed to assess the prostate for abnormalities.

Thirdly, imaging techniques such as magnetic resonance imaging (MRI) can help identify suspicious areas within the prostate and guide biopsy procedures.

Finally, a prostate biopsy provides tissue for microscopic examination. Pathologists evaluate the tissue to determine whether cancer cells are present and may assign a Gleason grade or Grade Group to characterize tumor aggressiveness.

Additional imaging and laboratory tests may be performed when physicians need to determine whether prostate cancer has spread beyond the prostate.

Treatment of Prostate Cancer

Treatment depends on several factors, including the stage and grade of cancer, whether the disease has spread, the patient’s overall health, and individual treatment preferences.

Firstly, active surveillance may be appropriate for some patients with localized, low-risk prostate cancer. Physicians monitor the disease through PSA testing, imaging, biopsies, and other assessments.

Secondly, surgery may be used to remove the prostate and surrounding tissues in selected patients. Radical prostatectomy is one surgical treatment for localized prostate cancer.

Thirdly, radiation therapy uses high-energy radiation to destroy cancer cells. External-beam radiation and brachytherapy are two commonly used approaches.

Fourthly, hormone therapy, also called androgen deprivation therapy, reduces or blocks the effects of male hormones that can stimulate prostate cancer growth.

Finally, physicians may use chemotherapy, targeted therapy, immunotherapy, or other systemic treatments for advanced or metastatic prostate cancer depending on the characteristics of the disease.

The Role of Prostate Cancer Biospecimens in Research

High-quality Prostate Cancer Biospecimens play an important role in advancing prostate cancer research and improving understanding of disease biology.

Firstly, Prostate Cancer Serum Samples enable researchers to investigate circulating biomarkers associated with prostate cancer development, progression, treatment response, and disease recurrence.

Secondly, Prostate Cancer Plasma Samples can support studies of circulating proteins, nucleic acids, tumor-derived materials, and other biomarkers that may contribute to diagnostic and prognostic research.

Thirdly, Prostate Cancer Tissue Samples allow researchers to investigate tumor morphology, molecular alterations, gene expression, and mechanisms involved in tumor growth and metastasis.

Moreover, Human Tumor Tissue Samples can support the development and validation of biomarkers and therapeutic targets.

Similarly, Fresh Frozen Tissue Samples are also useful for molecular, genomic, transcriptomic, and proteomic studies, while FFPE Tissue Samples can support histological and molecular investigations.

Frequently Asked Questions

What are Prostate Cancer Serum Samples used for?

Researchers use Prostate Cancer Serum Samples to investigate circulating biomarkers, disease progression, treatment response, and other biological characteristics of prostate cancer.

What are Prostate Cancer Plasma Samples used for?

Prostate Cancer Plasma Samples can support biomarker discovery, molecular research, translational studies, diagnostics development, and drug discovery.

Can customized prostate cancer collections be provided?

Yes. Please reach out to discuss your research requirements.

Supporting Your Research with Bay Biosciences

Bay Biosciences provides high-quality, clinical-grade, fully characterized human biospecimens for pharmaceutical, biotechnology, academic, and diagnostic research.

Our comprehensive collection of biospecimens includes:

If you have any questions, concerns, or special requests, please don’t hesitate to contact us.